Retatrutide

Peak Burn

Triple-pathway fat loss.

$299 AUD · $9.97/day · 30-day supply

Lyophilised powder vial · Subcutaneous injection · Self-administered

30-day full refund if you don't notice a difference. No return required.

24.2%
Mean body-weight reduction at 48 weeks
Jastreboff et al. · NEJM 2023
Australian Compounded
4.9 · 847 Reviews
30-Day Guarantee
Express Delivery AU-Wide

Mechanism

How Retatrutide Works.

Triple-receptor agonism. Three pathways, one compound — none previously combined at this potency.

Step 01

GLP-1 pathway

 

Slows gastric emptying and acts on hypothalamic satiety centres — you eat less without forcing it.

Step 02

GIP pathway

 

Amplifies the insulin response and enhances fat metabolism in adipose tissue.

Step 03

Glucagon pathway

 

Increases energy expenditure and liver fat oxidation — the piece that separates Retatrutide from dual agonists.

Clinical Data

The Research.

We cite the compound, not the product. These are Retatrutide's published results — the same compound in Peak Burn.

Jastreboff et al. · NEJM 2023 · Phase 2 Obesity Trial

"Retatrutide produced a 24.2% mean reduction in body weight at 48 weeks." At the top dose, 83% of participants lost at least 15% of body weight.

The largest weight-loss result published for any obesity pharmacotherapy at the time. PMID 37366315.

Triple-agonist mechanism · Eur J Med Chem 2026

Confirms simultaneous GLP-1 / GIP / glucagon receptor agonism as the class mechanism.

Retatrutide remains in Phase 3 development (TRIUMPH); not yet approved — supplied for research use.

Protocol

The Schedule.

The clinical trial used a progressive titration protocol. Below is the dosing schedule used in the NEJM Phase II trial.

Phase Duration Dose Frequency Expected Effect
Titration Weeks 1–4 2mg Once weekly Receptor priming — appetite changes begin
Escalation Weeks 5–8 4mg Once weekly Measurable body composition shift
Full Protocol Weeks 9–24 8mg Once weekly Sustained fat oxidation
Maintenance Weeks 25+ 8–12mg Once weekly Weight stabilisation

Dosing schedule based on the NEJM Phase II trial protocol. Not medical advice. Consult a healthcare professional before use.

Customer Results

They Ran It.

10,347 Australians
4.9★ · 847 reviews
1-in-3 re-order within 60 days
★★★★★
Down 11.4kg in 8 weeks on Burn. I’ve been on Ozempic before — the hunger suppression on Retatrutide is categorically different. No side effects. Just… food stopped being an obsession.
James T. — Sydney, 42, runs his own business — Burn (Retatrutide)
★★★★★
16kg in 12 weeks. My GP asked what I was doing. I told him. He asked me for the compound name and wrote it down. He’s looking into it for his other patients.
Karen M. — Brisbane, 47, nurse — Burn (Retatrutide)
★★★★★
I’d tried everything. Ozempic twice, a caloric deficit for 9 months, two personal trainers. Nothing moved the needle like this. Week 3 I knew something different was happening. 8 weeks in I’m down 9.2kg and I’m not hungry. I’m just not hungry.
Paul D. — Melbourne, 39, accountant — Burn (Retatrutide)

FAQ

Common Questions.

No. Ozempic and Wegovy contain Semaglutide — a GLP-1 single-receptor agonist. Retatrutide targets three receptors simultaneously: GLP-1, GIP, and glucagon. The Phase II trial data shows approximately double the body weight reduction of Semaglutide at equivalent duration. They operate on similar pathways, but Retatrutide is a fundamentally different compound in terms of mechanism and outcome.
Trial participants reported appetite changes within the first 2 weeks at the titration dose. Measurable body composition changes (scale weight, clothing fit) were typically reported at 4–6 weeks. The full effect compounded through weeks 8–24. Individual results vary based on starting weight, diet, and activity level.
The most common stack is Burn + Wolverine + Rewind. Wolverine (BPC-157 + TB-500) supports connective tissue during rapid body composition change — relevant if you're adding exercise. Rewind (NAD+) supports cellular energy systems during increased fat oxidation. There are no known compound interactions between Retatrutide and BPC-157, NAD+, or MOTS-C.
The NEJM Phase II trial reported mild-to-moderate nausea and reduced appetite in a subset of participants, consistent with the GLP-1 drug class. These were most common at the titration phase (weeks 1–4) and typically resolved as the body adapted. No serious adverse events were attributed to Retatrutide in the Phase II data. If you have a history of thyroid cancer, MEN2, or pancreatitis, consult a doctor before use — this is a compound-class caution across all GLP-1 agonists.
30-day full refund, no return required. We expect you to notice a difference — reduced appetite within 2 weeks, body composition change within 6. If you don't, we return your $299 in full. That reflects our confidence in what we compound, not a marketing softener.
Ships as lyophilised powder in a sterile vial. Reconstitute with bacteriostatic water using a fresh syringe and needle. Administer via subcutaneous injection — the lower abdomen or flank is the most common site. Rotate injection sites session to session. Ships stable at ambient temperature; refrigerate on arrival and use reconstituted solution within 21–28 days.
Standard workplace and roadside drug screens test for recreational substances and common medications — peptides will not appear on these screens. If you compete in a WADA-sanctioned sport, verify the current prohibited list at wada-ama.org before use, as regulations update annually. We recommend confirming with your sport's governing body before any sanctioned competition.